Newly found biomarkers 99 per cent accurate at differentiating between two types of ovarian cancer, according to º£½ÇÉçÇø researcher.
Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a co-led out of the º£½ÇÉçÇø.
"One of the issues with ovarian cancer is that we cannot fully decipher between subtypes," said Lynne Postovit, º£½ÇÉçÇø oncology researcher and co-director of the Cancer Research Institute of Northern Alberta. "This is an important problem because the different subtypes should be treated differently."
She explained that women with endometrioid-type ovarian carcinoma usually have a better prognosis for beating the disease and need a less aggressive treatment than women suffering from high-grade serous carcinomas, which is the most common and deadly form of ovarian cancer.